Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Astria Therapeutics ( (ATXS) ) has issued an update.
On June 11, 2025, Astria Therapeutics held its Annual Meeting of Stockholders, where several key decisions were made. The stockholders approved an amendment to the company’s stock incentive plan, increasing the shares available by 5.5 million, and elected three directors to the board. Additionally, Ernst & Young LLP was ratified as the independent auditor for the fiscal year, and the executive compensation was approved on an advisory basis.
The most recent analyst rating on (ATXS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page.
Spark’s Take on ATXS Stock
According to Spark, TipRanks’ AI Analyst, ATXS is a Neutral.
Astria Therapeutics’ stock score reflects its status as a development-stage biotech company. The strong balance sheet provides financial stability, but the lack of revenue and increasing losses pose significant risks. Mixed technical indicators and valuation challenges further contribute to a cautious outlook.
To see Spark’s full report on ATXS stock, click here.
More about Astria Therapeutics
Astria Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing therapies for rare and niche medical conditions.
Average Trading Volume: 478,232
Technical Sentiment Signal: Sell
Current Market Cap: $322.2M
See more data about ATXS stock on TipRanks’ Stock Analysis page.